Market Overview

The Drivers Behind HealthStream's 2018 Rally Are Unclear, Baird Says In Downgrade

The Drivers Behind HealthStream's 2018 Rally Are Unclear, Baird Says In Downgrade
Related HSTM
HealthStream's Earnings Preview
HealthStream Earnings Preview

Baird’s Matthew Gillmore downgraded HealthStream, Inc. (NASDAQ: HSTM) from Outperform to Neutral Thursday while maintaining a $24 price target. 

'Further Multiple Expansion Seems Unlikely' 

HealthStream’s share price had climbed an impressive 24 percent this year as of Wednesday’s close. Although the company has reported strong earnings the past two quarters, Gillmore said it's unclear what has driven the stock’s appreciation.

The stock is now in line with long-term average of about 3.3x forward revenue. “In our view, further multiple expansion seems unlikely, given HealthStream is a growth story and growth may be challenging during 2019-2020,” the analyst said in a note.

The reason for that stunted growth is the transition away from established resuscitation products, Gillmore said. The company announced last year that it would not renew its agreement with Laerdal to distribute its HeartCode and RQI products effective at the end of 2018.

Those products were lower-margin, but represented approximately 20 percent of HealthStream’s revenue — which most investors value the company by, the analyst said. 

2 Growth Opportunities 

HealthStream is working on new CPR solutions intended to replace the lost Laerdal revenue, Gillmore said. New information from the company could increase confidence in growth through 2020, particularly if it can leverage a strong brand partner, the analyst said. 

HealthStream has been shifting its business from content distribution toward content ownership and analytics. If all goes well, margins could expand faster than the analyst predicts, he said. 

“HealthStream is a uniquely positioned platform with solid growth prospects, but we think risk-reward is balanced at current levels." 

The Price Action

Shares of HealthStream spiked down 7 percent at Thursday’s open, but quickly recovered about half of that loss and were trading in the high-$27 handle midday. 

Related Links:

Benzinga's Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma's Q4 Miss, Sage Inks Deal With Japan's Shionogi

Galmed Shares More Than Double As It Hits Bullseye With Fatty Liver Candidate

Latest Ratings for HSTM

Jul 2018Barrington ResearchDowngradesOutperformMarket Perform
Jun 2018BairdDowngradesOutperformNeutral
Oct 2017BairdMaintainsOutperform

View More Analyst Ratings for HSTM
View the Latest Analyst Ratings

Posted-In: BairdAnalyst Color News Downgrades Health Care Price Target Analyst Ratings General Best of Benzinga


Related Articles (HSTM)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

The Enigmatic '50 Cent' VIX Trader Is Back

Mid-Day Market Update: Destination Maternity Climbs After Q1 Results; Tailored Brands Shares Slide